Skip to main content
Journal cover image

Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Publication ,  Conference
Saad, F; Armstrong, AJ; Thiery-Vuillemin, A; Oya, M; Shore, ND; Procopio, G; Arslan, C; Mehra, N; Parnis, F; Brown, E; Schlurmann, FC ...
Published in: ANNALS OF ONCOLOGY
2022

Duke Scholars

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

2022

Volume

33

Issue

7

Start / End Page

S1160 / S1160

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Saad, F., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N. D., Procopio, G., … Clarke, N. (2022). Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY (Vol. 33, pp. S1160–S1160).
Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann FC, Joung JY, Sugimoto M, Sartor O, Liu Y-Z, Poehlein CH, Desai C, Del Rosario PMD, Clarke N. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ANNALS OF ONCOLOGY. 2022. p. S1160–S1160.
Journal cover image

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

2022

Volume

33

Issue

7

Start / End Page

S1160 / S1160

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis